多発性骨髄腫治療薬市場：薬剤別、流通別-2023-2030年の世界予測

多発性骨髄腫治療薬の世界市場は、2023年に227億米ドル、CAGR 8.02%で大幅な成長が予測され、2030年には390億2,000万米ドルという驚異的な規模に達する見込みです。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは世界の多発性骨髄腫治療薬市場を評価するために不可欠です。ビジネス戦略と製品満足度の主要指標を調査することで、ベンダーの包括的な評価を提供し、ユーザーは特定のニーズに基づいた情報をもとに意思決定を行うことができます。この高度な分析により、ベンダーは成功の度合いが異なる4つの象限に整理されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析では、特定の市場領域におけるベンダーの現状を洞察することができます。全体的な収益、顧客基盤、その他の主要指標に対するベンダーの貢献度を比較することで、企業が市場シェアを争う際に、自社の業績や直面している状況をより深く理解することができます。また、本分析では、調査した基準年において、特定のセクターがどの程度競合しているのか、蓄積、断片化の優位性、合併の特徴についても明らかにしています。

本レポートは、以下のポイントに関する洞察を提供します：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提供します。

2.市場の発展：有利な新興市場に関する詳細情報を提供し、市場の成熟セグメントにおける浸透度を分析します。

3.市場の多様化：新製品の上市、未開発地域、最近の開発、投資に関する詳細情報を提供します。

4.市場の動向：COVID-19、ロシア・ウクライナ紛争、高インフレの累積的な影響を包括的に理解することができます。

5.競合の評価と情報：主要企業の市場シェア、戦略、製品、認証、規制状況、特許状況、製造能力を網羅的に評価します。

6.製品開発およびイノベーション：将来技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような質問にお答えします：

1.多発性骨髄腫治療薬の世界市場規模および予測は？

2.予測期間中、世界の多発性骨髄腫治療薬市場を形成するCOVID-19の阻害要因と影響は？

3.多発性骨髄腫治療薬の世界市場において予測期間中に投資すべき製品/セグメント/アプリケーション/分野は？

4.多発性骨髄腫治療薬の世界市場における競争戦略は？

5.多発性骨髄腫治療薬の世界市場における技術動向と規制の枠組みは？

6.多発性骨髄腫治療薬の世界市場における主要ベンダーの市場シェアは？

7.多発性骨髄腫治療薬の世界市場への参入には、どのような形態や戦略的な動きが適していると考えられるか？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 多発性骨髄腫の適応症と有病率の増加
    • 先進国での治療をサポートする魅力的な償還制度
    • ジェネリック医薬品の承認とともに医薬品の入手可能性が増加
  • 抑制要因
    • 厳格な医薬品承認プロセス
  • 機会
    • 製品開発と医薬品の治験および商品化の連携
    • 標的療法とコルチコステロイドの採用
  • 課題
    • 潜在的な副作用
• 市場動向
• COVID-19の累積的な影響
• ロシア・ウクライナ紛争の累積的影響
• 高インフレの累積的影響
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 規制の枠組み
• 顧客のカスタマイズ

第6章 多発性骨髄腫治療薬市場薬物別

• ヒストンデアセチラーゼ阻害剤
• 免疫調節剤
• モノクローナル抗体
• プロテアソーム阻害剤

第7章 多発性骨髄腫治療薬市場配信別

• 病院薬局
• オンラインチャンネル
• 小売薬局

第8章 南北アメリカの多発性骨髄腫治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋地域の多発性骨髄腫治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカの多発性骨髄腫治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• FPNVポジショニングマトリクス
• 市場シェア分析：主要企業別
• 競合シナリオ分析：主要企業別

第12章 掲載企業一覧

第13章 付録

• ディスカッションガイド
• ライセンスと価格について

LIST OF FIGURES

• FIGURE 1. MULTIPLE MYELOMA DRUG MARKET RESEARCH PROCESS
• FIGURE 2. MULTIPLE MYELOMA DRUG MARKET SIZE, 2022 VS 2030
• FIGURE 3. MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2022 VS 2030 (%)
• FIGURE 5. MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2022 VS 2030 (%)
• FIGURE 6. MULTIPLE MYELOMA DRUG MARKET SIZE, BY REGION, 2022 VS 2030 (%)
• FIGURE 7. MULTIPLE MYELOMA DRUG MARKET DYNAMICS
• FIGURE 8. MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 9. MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 11. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 12. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 13. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 14. MULTIPLE MYELOMA DRUG MARKET, FPNV POSITIONING MATRIX, 2022
• FIGURE 15. MULTIPLE MYELOMA DRUG MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

• TABLE 1. MULTIPLE MYELOMA DRUG MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
• TABLE 3. MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 5. MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 6. MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 7. MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 8. MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 10. MULTIPLE MYELOMA DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. MULTIPLE MYELOMA DRUG MARKET SIZE, BY ONLINE CHANNEL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. MULTIPLE MYELOMA DRUG MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 14. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 15. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 16. ARGENTINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 17. ARGENTINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 18. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 19. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 20. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 21. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 22. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 23. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 24. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 25. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 26. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 27. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 28. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 29. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 30. AUSTRALIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 31. AUSTRALIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 32. CHINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 33. CHINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 34. INDIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 35. INDIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 36. INDONESIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 37. INDONESIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 38. JAPAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 39. JAPAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 40. MALAYSIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 41. MALAYSIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 42. PHILIPPINES MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 43. PHILIPPINES MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 44. SINGAPORE MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 45. SINGAPORE MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 46. SOUTH KOREA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 47. SOUTH KOREA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 48. TAIWAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 49. TAIWAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 50. THAILAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 51. THAILAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 52. VIETNAM MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 53. VIETNAM MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 54. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 55. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 56. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 57. DENMARK MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 58. DENMARK MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 59. EGYPT MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 60. EGYPT MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 61. FINLAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 62. FINLAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 63. FRANCE MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 64. FRANCE MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 65. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 66. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 67. ISRAEL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 68. ISRAEL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 69. ITALY MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 70. ITALY MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 71. NETHERLANDS MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 72. NETHERLANDS MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 73. NIGERIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 74. NIGERIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 75. NORWAY MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 76. NORWAY MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 77. POLAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 78. POLAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 79. QATAR MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 80. QATAR MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 81. RUSSIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 82. RUSSIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 83. SAUDI ARABIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 84. SAUDI ARABIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 85. SOUTH AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 87. SPAIN MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 88. SPAIN MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 89. SWEDEN MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 90. SWEDEN MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 91. SWITZERLAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 92. SWITZERLAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 93. TURKEY MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 94. TURKEY MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 95. UNITED ARAB EMIRATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 96. UNITED ARAB EMIRATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 97. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 98. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 99. MULTIPLE MYELOMA DRUG MARKET, FPNV POSITIONING MATRIX, 2022
• TABLE 100. MULTIPLE MYELOMA DRUG MARKET SHARE, BY KEY PLAYER, 2022
• TABLE 101. MULTIPLE MYELOMA DRUG MARKET LICENSE & PRICING

The Global Multiple Myeloma Drug Market is forecasted to grow significantly, with a projected USD 22.70 billion in 2023 at a CAGR of 8.02% and expected to reach a staggering USD 39.02 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Multiple Myeloma Drug Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Multiple Myeloma Drug Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Drug, market is studied across Histone Deacetylase Inhibitors, Immunomodulating Agents, Monoclonal Antibodies, and Proteasome Inhibitors. The Proteasome Inhibitors is projected to witness significant market share during forecast period.

Based on Distribution, market is studied across Hospital Pharmacy, Online Channel, and Retail Pharmacy. The Hospital Pharmacy is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Multiple Myeloma Drug Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Multiple Myeloma Drug Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Multiple Myeloma Drug Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Multiple Myeloma Drug Market?

4. What is the competitive strategic window for opportunities in the Global Multiple Myeloma Drug Market?

5. What are the technology trends and regulatory frameworks in the Global Multiple Myeloma Drug Market?

6. What is the market share of the leading vendors in the Global Multiple Myeloma Drug Market?

7. What modes and strategic moves are considered suitable for entering the Global Multiple Myeloma Drug Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Multiple Myeloma Drug Market, by Drug, 2022 vs 2030
• 4.3. Multiple Myeloma Drug Market, by Distribution, 2022 vs 2030
• 4.4. Multiple Myeloma Drug Market, by Region, 2022 vs 2030

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increased indication and prevalence of Multiple Myeloma
    • 5.1.1.2. Attractive reimbursement policies supporting treatments in developed countries
    • 5.1.1.3. Increased drug availability along with approvals for generics
  • 5.1.2. Restraints
    • 5.1.2.1. Stringent drug approval process
  • 5.1.3. Opportunities
    • 5.1.3.1. Collaborating product development and drug trials and commercialization
    • 5.1.3.2. Targeted therapy and adoption of Corticosteroids
  • 5.1.4. Challenges
    • 5.1.4.1. Potential side effects
• 5.2. Market Trends
• 5.3. Cumulative Impact of COVID-19
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework
• 5.9. Client Customization

6. Multiple Myeloma Drug Market, by Drug

• 6.1. Introduction
• 6.2. Histone Deacetylase Inhibitors
• 6.3. Immunomodulating Agents
• 6.4. Monoclonal Antibodies
• 6.5. Proteasome Inhibitors

7. Multiple Myeloma Drug Market, by Distribution

• 7.1. Introduction
• 7.2. Hospital Pharmacy
• 7.3. Online Channel
• 7.4. Retail Pharmacy

8. Americas Multiple Myeloma Drug Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Multiple Myeloma Drug Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Multiple Myeloma Drug Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. FPNV Positioning Matrix
• 11.2. Market Share Analysis, By Key Player
• 11.3. Competitive Scenario Analysis, By Key Player

12. List of Company Mentioned

13. Appendix

• 13.1. Discussion Guide
• 13.2. License & Pricing